Institutional Ownership
Gain Therapeutics Inc
CUSIP 36269B105COMGANXQ1 2026
13D / 13G Filings
1
Schedule 13D/13G on record
Beneficial Filers
1
Distinct reporting persons
Largest Stake
6.1%
Max % of class reported
Institutional Holders
39
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
1 filings · latest Mar 29, 2021
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 29, 2021 | Titcomb Shawn | 13G/A | 6.1% | 729.7K | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Marshall Wace, LLP | 1.77M | $3.43M |
| 2 | Potomac Capital Management, Inc. | 1.01M | $1.96M |
| 3 | Jones Financial Companies Lllp | 631.6K | $1.16M |
| 4 | Dme Capital Management, LP | 566.1K | $1.10M |
| 5 | Geode Capital Management, LLC | 447.3K | $868.5K |
| 6 | Susquehanna International Group, LLP | 431.3K | $836.7K |
| 7 | Blackrock, Inc. | 225.0K | $436.6K |
| 8 | Ubs Group AG | 220.5K | $427.7K |
| 9 | Jane Street Group, LLC | 216.9K | $420.8K |
| 10 | Cresset Asset Management, LLC | 160.0K | $310.4K |